


IN THE CLAIMS:



Please amend the claims as follows:

1. (Currently Amended). A pharmaceutically acceptable salt of formula (I)



its stereoisomers, ~~its polymorphs, or its solvates~~ wherein R^1 represents ~~hydrogen~~ alkyl or aryl group ethyl; M represents ~~a counter ion or a moiety which forms a pharmaceutically acceptable salt~~ phenyl glycinol, methyl benzylamine, dicyclohexylamine, tris (hydroxymethyl)amino methane, N-octyl glucamine, N-methyl glucamine, amino guanidine hydrogen carbonate, metformin, imidazole, methyl benzylamine, S-(+)-phenylglycinol, aminoguanidine, tromethamine, t-butylamine, tris (hydroxymethyl) amino methane; p is an integer ranging from 1 to 2;

A represents a cyclic structure given below:



wherein R^2 and R^3 are the same or different and independently represent ~~hydrogen, halogen, hydroxyl, nitro, cyano, alkyl or alkoxy group~~ represents methyl; R^3 represents ethyl, propyl; R^4 represents ~~hydrogen, halogen, hydroxyl, nitro, cyano, azido, formyl or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, aryl heterocyclyl, heteroaryl, amino, monoalkylaminino, dialkylamino or alkoxyalkyl groups~~ methyl, ethyl, azido, morpholinyl, piperidinyl.

2. (Canceled)
3. (Withdrawn). A pharmaceutical composition which comprises a compound as claimed in claim 1 and a pharmaceutically acceptable carrier, diluent, excipient or solvate.
4. (Withdrawn). A composition which comprises a compound as claimed in claim 1, and an HMG CoA reductase inhibitor, fibrate, nicotinic acid, cholestyramine, cholestipol, probucol or a mixture thereof and a pharmaceutically acceptable carrier, diluent, excipient or solvate.
5. (Withdrawn). A pharmaceutical composition as claimed in claim 3, in the form of a tablet, capsule, powder, syrup, solution or suspension.
6. (Withdrawn). A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia osteoporosis, obesity, impaired glucose tolerance, atherosclerosis, leptin resistance, insulin resistance or diseases in which insulin resistance is the underlying pathophysiological mechanism comprising administering a compound of formula (I) as defined in claim 1 to a patient in need thereof.
7. (Withdrawn). A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, osteoporosis, obesity, impaired glucose tolerance, atherosclerosis, leptin resistance, insulin resistance or diseases in which insulin resistance is the

underlying pathophysiological mechanism comprising administering a composition as defined in claim 4 to a patient in need thereof.

8. (Withdrawn). A method according to claim 6, wherein the disease is type II diabetes, impaired glucose tolerance, disorders related to Syndrome X selected from hypertension, obesity, insulin resistance, atherosclerosis, coronary artery disease or other cardiovascular disorders; renal diseases selected from glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, or nephropathy; retinopathy, disorders to related endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), dementia, diabetic complications, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma, eating disorders, cancer, osteoporosis or inflammation.

9. (Withdrawn). A method according to claim 7, wherein the disease is type II diabetes, impaired glucose tolerance, disorders related to Syndrome X selected from hypertension, obesity, insulin resistance, atherosclerosis, coronary artery disease or other cardiovascular disorders; renal diseases selected from glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, or nephropathy; retinopathy, disorders to related endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), dementia, diabetic complications, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma, eating disorders, cancer, osteoporosis or inflammation.

10. (Withdrawn). A method for the treatment of disorders related to Syndrome X, which comprises administering an agonist of PPAR α and/or PPAR γ of formula (I) as claimed in claim 1 to a patient in need thereof.

11-12. (Canceled)

13. (Currently Amended). A pharmaceutical composition which comprises a compound as claimed in claim ~~14~~ 1 and a pharmaceutically acceptable carrier, diluent, excipient or solvate.

14. (Currently Amended). A pharmaceutical composition which comprises a compound ~~of formula I~~ as defined in claim 1, and an HMG CoA reductase inhibitor, fibrate, nicotinic acid, cholestyramine, cholestipol, probucol or a mixture thereof and a pharmaceutically acceptable carrier, diluent, excipient or solvate.

15-16. (Canceled)

17. (Original). A pharmaceutical composition as claimed in claim 13, in the form of a tablet, capsule, powder, syrup, solution or suspension.

18. (Original). A pharmaceutical composition as claimed in claim 14, in the form of a tablet, capsule, powder, syrup, solution or suspension.

19. (Canceled)

20-23 (Canceled)

24. (Currently Amended). A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia ~~osteoporosis~~, obesity, impaired glucose tolerance, atherosclerosis, leptin resistance, insulin resistance or diseases in which insulin resistance is the underlying pathophysiological mechanism comprising

administering a compound of formula (I) as defined in claim 1 to a patient in need thereof.

25-27. (Canceled)

28. (Currently Amended). A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, ~~osteoporosis~~, obesity, impaired glucose tolerance, atherosclerosis, leptin resistance, insulin resistance or diseases in which insulin resistance is the underlying pathophysiological mechanism comprising administering a composition as defined in claim 14 to a patient in need thereof.

29. (Canceled)

30. (Currently Amended). A method according to claim 24, wherein the disease is type II diabetes, impaired glucose tolerance, disorders related to Syndrome X selected from hypertension, obesity, insulin resistance, atherosclerosis, coronary artery disease or other cardiovascular disorders; ~~renal diseases selected from glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, or nephropathy~~; retinopathy, ~~disorders to related endothelial cell activation~~, psoriasis, ~~polycystic ovarian syndrome (PCOS)~~, ~~dementia~~, diabetic complications, inflammatory bowel diseases, ~~myotonic dystrophy~~, pancreatitis, arteriosclerosis, xanthoma, ~~eating disorders~~, cancer, ~~osteoporosis~~ or inflammation.

31-33 (Canceled).

34. (Currently Amended). A method according to claim 28, wherein the disease is type II diabetes, impaired glucose tolerance, disorders related to Syndrome X selected from hypertension, obesity, insulin resistance, atherosclerosis, coronary artery disease or other cardiovascular disorders; ~~renal diseases selected from glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, or nephropathy~~; retinopathy, ~~disorders to related endothelial cell activation~~, psoriasis, ~~polycystic ovarian syndrome (PCOS)~~, ~~dementia~~, diabetic complications, inflammatory bowel diseases, ~~myotonic dystrophy~~, pancreatitis, arteriosclerosis, xanthoma, ~~eating disorders~~, cancer, ~~osteoporosis~~ or inflammation.

35. (Canceled)

36. (Original). A method for the treatment of disorders related to Syndrome X, which comprises administering an agonist of PPAR α and/or PPAR γ of formula (I) as claimed in claim 1 to a patient in need thereof.

37-39. (Canceled)

40. (Original). A method for the treatment of disorders related to Syndrome X, which comprises administering a pharmaceutical composition according to claim 14 comprising an agonist of PPAR α and/or PPAR γ to a patient in need thereof.

41 (Canceled)

42. (Original). A method of reducing total cholesterol, body weight, blood plasma glucose, triglycerides, LDL, VLDL or free fatty acids or increasing HDL in the plasma comprising administering a compound of formula (I) according to claim 1 to a patient in need thereof.

43-47 (Canceled).

48. (Currently Amended). A method of treating hyperlipemia, hypercholesteremia, hyperglycemia, ~~osteoporosis~~, obesity, impaired glucose tolerance, atherosclerosis, leptin resistance, insulin resistance, or diseases in which insulin resistance is the underlying pathophysiological mechanism comprising administering to a patient in need thereof an effective amount of a compound of formula (I) as defined in claim 1 in combination/concomittant with a HMG CoA reductase inhibitor, fibrate, nicotinic acid, cholestyramine, colestipol or probucol or a mixture thereof within such a period so as to act synergistically.

49-51 (Canceled).

52. (Currently Amended). A method according to claim 48, wherein the disease is type II diabetes, impaired glucose tolerance, disorders related to Syndrome X selected from hypertension, obesity, insulin resistance, atherosclerosis, coronary artery disease or other cardiovascular disorders; ~~renal diseases selected from glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, or nephropathy~~; retinopathy, disorders to

~~related endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), dementia, diabetic complications, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma, eating disorders, cancer, osteoporosis or inflammation.~~

53-55. (Canceled)

56. (Original). A method for the treatment of disorders related to Syndrome X, which comprises administering to a patient in need thereof an agonist of PPAR α and/or PPAR γ of formula (I) as claimed in claim 1 in combination/concomittant with a HMG CoA reductase inhibitor, fibrate, nicotinic acid, cholestyramine, colestipol or probucol or a mixture thereof within such a period as to act synergistically.

57-59 (Canceled).

60. (Original). A method of reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL or free fatty acids or increasing HDL in the plasma, which comprises administering a compound of formula (I) claimed in claim 1, in combination/concomittant with a HMG CoA reductase inhibitor, fibrate, nicotinic acid, cholestyramine, colestipol or probucol or a mixture thereof which may be administered together or within such a period as to act synergistically together to a patient in need thereof.

61-63. (Canceled)

64. (Withdrawn). The process as claimed in claim 5, wherein the alcohol is selected from a group consisting of ethanol, methanol, isopropanol and butanol; ketone is selected from a group consisting of acetone, diethyl ketone, and methyl ethyl ketone; and ether is selected from a group consisting of diethyl ether, ether, tetrahydrofuran, dioxane, and dibutyl ether.

65. (Withdrawn). The process as claimed in claim 6 wherein the alcohol is selected from a group consisting of ethanol, methanol, isopropanol and butanol; ketone is selected from a group consisting of acetone, diethyl ketone, and methyl ethyl ketone; and ether is selected from a group consisting of diethyl ether, ether, tetrahydrofuran, dioxane, and dibutyl ether.

Please add the following claims:

66. (New). The pharmaceutically acceptable salt according to claim 1, which is selected from:

(±) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid phenyl glycinol salt;

(+) 3- [4- [2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid phenyl glycinol salt;

(-) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid phenyl glycinol salt;

(±) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid methyl benzylamine salt;

(+) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid methyl benzylamine salt;

(-) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid methyl benzylamine salt;

(±) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid dicyclohexylamine salt;

(+) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid dicyclohexylamine salt;

(-) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid dicyclohexylamine salt;

(±) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid tris (hydroxymethyl)amino methane salt

(+) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid tris (hydroxymethyl)amino methane salt;

(-) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid tris (hydroxymethyl)amino methane salt;

(±) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid N-octyl glucamine salt;

(+) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid N-octyl glucamine salt;

(-) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid N-octyl glucamine salt;

(±) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid N-methyl glucamine salt;

(+) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid N-methyl glucamine salt;

(-) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid N-methyl glucamine salt;

(±) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid amino guanidine hydrogen carbonate salt;

(+) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid amino guanidine hydrogen carbonate salt;

(-) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid amino guanidine hydrogen carbonate salt;

(±) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid lithium salt;

(+) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid lithium salt;

(-) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid lithium salt;

(±) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid metformin salt;

(+) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid metformin salt ;

(-) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]
phenyl]-2-ethoxypropanoic acid metformin salt ;

(±) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]phenyl]-2-ethoxypropanoic acid imidazole salt;

(+) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]phenyl]-2-ethoxypropanoic acid imidazole salt;

(-) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]phenyl]-2-ethoxypropanoic acid imidazole salt.

67. (New). The pharmaceutically acceptable salt according to claim 1, which is selected from:

(±)3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid methyl benzylamine salt;

(+)3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid methyl benzylamine salt;

(-)3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid methyl benzylamine salt;

(±)3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid S-(+)-phenylglycinol salt;

(+)3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid S-(+)-phenylglycinol salt;

(-)3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid S-(+)-phenylglycinol salt;

(±)3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid amino-guanidine salt;

(+)3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid amino-guanidine salt;

(-) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid amino-guanidine salt;

(±) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid tromethamine salt;

(+) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid tromethamine salt;

(-) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid tromethamine salt;

(±) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid dicyclohexylamine salt;

(+) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid dicyclohexylamine salt;

(-) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid dicyclohexylamine salt;

(±) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid N-octyl-glucamine salt;

(+) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid N-octyl-glucamine salt;

(-) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid N-octyl-glucamine salt;

(±) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3 -d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid N-methyl-glucamine salt;

(+) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid N-methyl-glucamine salt;

(-) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid N-methyl-glucamine salt;

(±) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid metformin salt;

(+) 3-[4-[2-(1-Methyl-5 -ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid metformin salt;

(-) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-prop yl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid metformin salt;

(±) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid tbutylamine salt;

(+) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid tbutylamine salt;

(-) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid tbutylamine salt;

(±)-3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid aminoguanidine hydrogen carbonate salt;

(+)-3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid aminoguanidine hydrogen carbonate salt;

(-)-3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid aminoguanidine hydrogen carbonate salt.

68. (New.) The pharmaceutically acceptable salt according to claim 1, which is selected from:

(±) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid methyl benzylamine salt;

(+) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid methyl benzylamine salt;

(-) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid methyl benzylamine salt;

(±) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyridin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid S-(+)-phenylglycinol salt;

(+) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid S-(+)-phenylglycinol salt;

(-) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid S-(+)-phenylglycinol salt;

(±) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid amino-guanidine salt;

(+) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid amino-guanidine salt;

(-) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid amino-guanidine salt;

(±) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid tromethamine salt;

(+) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid tromethamine salt;

(-) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid tromethamine salt;

(±) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid dicyclohexylamine salt;

(+) 3- [4- [2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3- d]pyrimidin- 6-yl)ethoxy]phenyl]-2-ethoxypropionic acid dicyclohexylamine salt;

(-) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1 H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid dicyclohexylamine salt;

(±) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro- 1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid N-octylglucamine salt;

(+) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro- 1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid N-octylglucamine salt;

(-) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid N-octylglucamine salt;

(±) 3- [4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro- 1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid N-methylglucamine salt;

(+) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid N-methylglucamine salt;

(-) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid N-methylglucamine salt;

(±) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid metformin salt;

(+) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1 H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid metformin salt;

(-) 3-[4-[2-(1,5-Dimethyl-7-oxo-3 -propyl-6,7-dihydro-1 H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid metformin salt;

(±) 3- [4-[2-(1,5-Dimethyl-7-oxo-3 -propyl-6,7-dihydro- 1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropⁱo^{nic} acid tbutylamine salt;

(+) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1 H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid tbutylamine salt;

(-) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1 H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid tbutylamine salt;

(±) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid aminoguanidine hydrogen carbonate salt;

(+) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxy propionic acid aminoguanidine hydrogen carbonate salt;

(-) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid aminoguanidine hydrogen carbonate salt;

69. (New). The pharmaceutically acceptable salt according to claim 1, which is selected from:

(±) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid phenyl glycinol salt;

(+) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid phenyl glycinol salt;

(-) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid phenyl glycinol salt;

(±) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid methyl benzylamine salt;

(+) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid methyl benzylamine salt;

(-) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid methyl benzylamine salt;

(±) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid t-butylamine salt;

(+) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid t-butylamine salt;

(-) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid t-butylamine salt;

(±) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid N-methyl glucamine salt;

(+) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid N-methyl glucamine salt;

(-) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid N-methyl glucamine salt;

(±) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid N-octyl glucamine salt;

(+) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid N-octyl glucamine salt;

(-) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid N-octyl glucamine salt;

(±) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid tris (hydroxymethyl) amino methane salt;

(+) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid tris (hydroxymethyl) amino methane salt;

(-) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid tris (hydroxymethyl) amino methane salt;

(±) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid lithium salt;

(+) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid lithium salt;

(-) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid lithium salt;

(±) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid metformin salt;

(+) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid metformin salt;

(-) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid metformin salt;

(±) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid dicyclohexylamine salt;

(+) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid dicyclohexylamine salt;

(-) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid dicyclohexylamine salt;

(±) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid aminoguanidine salt;

(+) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid aminoguanidine salt;

(-) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid aminoguanidine salt;